secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123369
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M
--------------------------------------------------------------------------------

- Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).
- Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.
- clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.
- MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.
- Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/0000950170-24-123369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024123369/adpt-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer